Article
CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Pharmacogenomics - 1 Feb 2014
Kurzawski Mateusz, Dąbrowska Justyna, Dziewanowski Krzysztof, Domański Leszek, Perużyńska Magdalena, Droździk Marek
Abstract excerpt
BACKGROUND: Tacrolimus (TAC), acting as a calcineurin inhibitor, is an immunosuppressant widely used after kidney transplantation. TAC requires blood concentration monitoring due to large interindividual variability in its pharmacokinetics and a narrow therapeutic index. Since genetic factors are considered responsible for a part of the observed pharmacokinetic variability, hereby SNPs within the CYP3A4, CYP3A5...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
